Biocryst Pharmaceuticals

Biocryst Pharmaceuticals

BCRX· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock +3.7% in FY2025

Charles K. Gayer is the CEO of Biocryst Pharmaceuticals and was paid $9.6M in FY2025 (Dec), up 185%.

Pay$100 in the stock at the end of FY21 → $56
CEO pay is from each Biocryst Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives6

See all
  1. 1Charles K. GayerFY2025
  2. 2Jon P. StonehouseFY2024
  3. 3Babar GhiasFY2025
  4. 4Alane P. BarnesFY2025
  5. 5Helen M. Thackray, M.D.FY2025
  6. 6Anthony J. DoyleFY2024

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Biocryst Pharmaceuticals paid its 4 named executives $26.3M in total in FY2025 (Dec). CEO Charles K. Gayer was paid $9.6M of that.

Name
Charles K. GayerPresident and Chief Executive Officer; Former Chief Commercial Officer
Babar GhiasChief Financial OfficerNot disclosedNot disclosed
Alane P. BarnesChief Legal Officer and Corporate Secretary
Helen M. Thackray, M.D.Former Chief R&D Officer
Jon P. StonehouseFormer President and Chief Executive OfficerNot disclosed
Anthony J. DoyleFormer Chief Financial Officer and TreasurerNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers18

See all

The FY2025 (Dec) proxy of Biocryst Pharmaceuticals names 18 peer companies for pay. Pay versus performance data of Biocryst Pharmaceuticals for that year is not on file, so it has no rank.

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board4

See all
  • Theresa M. HeggieDirector · 7 yr on the boardIndependentAudit, Corporate Governance and Nominating—Paid as an executive
  • Alan G. LevinDirector · 5 yr on the boardIndependentAudit (Chair)—Paid as an executive
  • Amy E. McKee, M.D.Director · 4 yr on the boardIndependentCorporate Governance and Nominating—Paid as an executive
  • A. Machelle SandersDirector · 3 yr on the boardIndependentCompensation (Chair)—Paid as an executive

The board of the latest proxy (FY2025).

Activity

  1. Pay
    Biocryst Pharmaceuticals Former Chief R&D Officer pay rose 22% to $4.3M. The stock rose 4% in FY2025 (Dec).
    DEF 14A
  2. Pay
    Biocryst Pharmaceuticals CEO pay rose 185% to $9.6M. The stock rose 4% in FY2025 (Dec).
    DEF 14A
  3. Pay
    Biocryst Pharmaceuticals General counsel pay rose 73% to $5.6M. The stock rose 4% in FY2025 (Dec).
    DEF 14A
  4. Pay
    Biocryst Pharmaceuticals President pay rose 74% to $8.3M. The stock rose 26% in FY2024 (Dec).
    DEF 14A
  5. Pay
    Biocryst Pharmaceuticals Former Chief R&D Officer pay rose 49% to $3.6M. The stock rose 26% in FY2024 (Dec).
    DEF 14A
  6. Pay
    Biocryst Pharmaceuticals CEO pay rose 94% to $3.4M. The stock rose 26% in FY2024 (Dec).
    DEF 14A
  7. Pay
    Biocryst Pharmaceuticals Former CFO pay rose 84% to $3.3M. The stock rose 26% in FY2024 (Dec).
    DEF 14A
  8. Pay
    Biocryst Pharmaceuticals General counsel pay rose 68% to $3.2M. The stock rose 26% in FY2024 (Dec).
    DEF 14A
  9. Pay
    Biocryst Pharmaceuticals President pay fell 32% to $4.8M. The stock fell 48% in FY2023 (Dec).
    DEF 14A
  10. Pay
    Biocryst Pharmaceuticals Former Chief R&D Officer pay fell 32% to $2.4M. The stock fell 48% in FY2023 (Dec).
    DEF 14A
  11. Pay
    Biocryst Pharmaceuticals Former Chief R&D Officer pay fell 49% to $3.5M. The stock fell 17% in FY2022 (Dec).
    DEF 14A
  12. Pay
    Biocryst Pharmaceuticals CEO pay fell 21% to $1.7M. The stock fell 48% in FY2023 (Dec).
    DEF 14A
  13. Pay
    Biocryst Pharmaceuticals Former CFO pay fell 22% to $1.8M. The stock fell 48% in FY2023 (Dec).
    DEF 14A
  14. Pay
    Biocryst Pharmaceuticals Former CFO pay fell 21% to $2.3M. The stock fell 17% in FY2022 (Dec).
    DEF 14A
  15. Pay
    Biocryst Pharmaceuticals General counsel pay fell 13% to $1.9M. The stock fell 48% in FY2023 (Dec).
    DEF 14A

Filings6

See all
Proxy statementDEF 14AApr 23, 2026FY2025
Annual report10-KFeb 26, 2026FY2025
Proxy statementDEF 14AApr 24, 2025FY2024
Annual report10-KFeb 25, 2025FY2024
Proxy statementDEF 14AApr 25, 2024FY2023
Annual report10-KFeb 27, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data